MYRA-B (NSC45641) is a small molecule that induces Myc-dependent apoptosis without affecting Myc transactivation or Myc/Max DNA binding.

NSC13728 is a specific small molecule stabilizer of the Max homodimer inhibiting Myc function, also inhibits Myc-Max heterodimerization.

NSC13728 hydrochloride is a specific small molecule stabilizer of the Max homodimer inhibiting Myc function, also inhibits Myc-Max heterodimerization.

VPC-70619 (VPC70619) is a selective small-molecule inhibitor of N-Myc transcription in NMYC transcription inhibition assays.

ATF3W-aeg peptide is a selective, peptide inhibitor of activating transcription factor 3 (ATF3) with high affinity (Kd=151 nM), increases CCL4 expression levels in human macrophages.

CIDD-0149897 is a potent, selective, brain permeable estrogen receptor beta (ERβ) agonist, 40-fold selective over ERα.

SLU-PP-332 is a potent, selective pan ERRα/β/γ agonist with EC50 of 98, 230 and 430 nM for ERRα, ERRβ and ERRγ, in full-length ERR cell-based cotransfection/reporter assays.

SLU-PP-915 is a potent pan-ERR (Estrogen-related receptor) nuclear receptor agonist with EC50 of 414/435/378 nM for ERRα/ERRβ/ERRγ, respectively.

SMIP34 (Small Molecule Inhibitor of PELP1 34) is a first-in-class, small molecule inhibitor of estrogen receptor (ER) coregulator PELP1, binds to (Kd=37.4 uM) and reduces PELP1 oncogenic functions.

X15695 is a potent, selective and orally active estrogen receptor alpha (ERα) degrader, destabilizes ERα and stabilizes p53, inhibits ER+ breast cancer cell growth.

eEF2K degrader C1 is a small-molecule degrader of eEF2K, acts a molecular glue to enhance the interaction of eEF2K with the ubiquitin E3 ligase βTRCP, thereby promoting the proteasomal degradation of eEF2K.

MG-002 is a potent, second-generation, orally bioavailable eIF4A RNA helicase inhibitor, potently inhibits cap-dependent mRNA translation with IC50 of 43 nM.

RBF197 (RBF-197) is a novel highly potent and selective eIF4A inhibitor, inhibits human eIF4A helicase activity with IC50 of 55.2 pM.

SBI-0498 (SBI-0730498) is a small molecule inhibitor of coronaviruses translation initiation complex 4F (eIF4F), disrupts eIF4F complex formation and inhibits coronavirus RNA and protein levels.

SBI-5844 (SBI-1275844) is a small molecule inhibitor of coronaviruses translation initiation complex 4F (eIF4F), disrupts eIF4F complex formation and inhibits coronavirus RNA and protein levels.

HPG1860 is a potent, selective, nonbile acid full FXR agonist with EC50 of 5 nM and 18 nM in FR-FRET and luciferase assays, respectively.

ID119031166 (ID166) is a novel potent, selective FXR agonist with EC50 of 3 nM and 5 nM in TR-FRET FXR co-activator assay and FXR reporter assay, respectively.

MET409 (MET-409) is a potent, selective farnesoid X receptor (FXR) agonist with EC50 of 16 nM (human FXR).

PDL103 is a potent, dual FXR/GPBAR1 antagonist with IC50 of 10 and 19 uM, respectively.

3i-1262 is a small molecule GATA4-acting compound that inhibit the GATA4-NKX2-5 interaction, enhances cardiomyocyte identity and maturity.

ER-400583-00 is a small-molecule HIF-1α inhibitor, inhibits the induction of HIF-1 reporter activity in response to hypoxia with IC50 of 7.9 nM.

FG-0041 (FG0041) is a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase (HIF-PH) with IC50 of 2 uM for collagen prolyl hydroxylase.

MO-2097 is a small molecule hnRNPA2B1-binding compound (ITC KD=43.1 uM) that suppresses hnRNPA2B1-induced HIF-1α protein expression under hypoxic and mimetic hypoxia.

D-F07 is a novel fluorescent, covalent IRE-1 inhibitor, potently inhibits XBP-1s expression in MM cells.

PAIR1 is a partial antagonist of IRE1α RNase (PAIR) that fully engage IRE1α's kinase domain (Ki=220 nM) but only partially inhibit its RNase activity.

TC-D-F07 is a novel prodrug of the covalent IRE-1 inhibitor D-F07, inhibits IRE-1/XBP-1s pathway in cancer cells.

BC-1901S is a potent small molecule NRF2 activator that stabilizes NRF2 and increases NRF2 activity, activates NRF2 by inhibiting NRF2 ubiquitination in a KEAP1-independent manner.

S217879 (S 217879) is a highly potent and selective NRF2 activator, binds to KEAP1 Kelch domain (SPR Kd=4.15 nM), disrupts the KEAP1-NRF2 interaction leading to robust NRF2 pathway activation.

sAKZ692 (sAKZ-692) is a small molecule activator of NRF2 transcriptional activity (EC50=2.2 uM) in cells by inhibiting the glycolytic enzyme pyruvate kinase.

NC114 is a small molecule targeting cancer-associated KLF5 transcription factor, decreases the KLF protein but not mRNA levels of KLF in vitro.

4A7C-301 is a potent, selective, brain-penetrant agonist of nuclear receptor Nurr1 with EC50 of 6.53 uM, binds to Nurr1 ligand binding domain (LBD) with IC50 of 50 nM.

BRF110 is a potent, selective, brain penetrant and vivo active agonist of Nurr1-RXRα heterodimers with EC50 of 900 nM.

SA00025 is a potent, specific and brain penetrant agonist of Nurr1 (NR4A2) with EC50 of 2.5 nM in HEK293 cells transfected with full length human Nurr1.

XCT0135908 (BRF001) is a highly selective activator of Nurr1-RXR heterodimers, stimulates dopamine (DA) neuron survival.

MBX-102 acid is the active form of JNJ39659100 (MBX-102), a selective partial PPAR-γ agonist with EC50 of 23.34 uM (hPPAR-γ), enhances insulin sensitivity in vitro in 3T3-L1 adipocytes, binds to the PPAR-γ LBD in a manner that is distinct from but overla

MMT-160 is a novel selective peroxisome proliferator-activated receptor γ (PPARγ) antagonist with IC50 of 0.17 uM, covalently binds to the PPARγ ligand binding domain (LBD) via Cys285.

SR10221 is a potent, selective PPARγ inverse agonist with IC50 of 13 nM in biochemical peptide recruitment assays, represses downstream PPARγ target genes leading to growth inhibition in bladder cancer cell lines.

FKK6 (Felix Kopp Kortagere 6) is a specific human pregnane X receptor (hPXR) agonist with IC50 of 1.56 uM in a cell-free competitive hPXR TR-FRET-binding assays.

SJPYT-318 is a highly selective pregnane X receptor (PXR) agonist, targets PXR ligand-binding domain (LBD), exhibits selectivity for PXR LBD over LXR LBDs for recruiting SRC-1.

A small molecule inhibitor of progesterone receptor membrane component 1 (PGRMC1) that alters the spectroscopic properties of the PGRMC1-heme complex.

AGN 196996 (IRX6696) is a potent selective RARα antagonist with Ki of 2 nM, shows little to no activity against RARβ and RARγ.

BPA-B9 (Bipyridine amide B9) is a small molecule RXRα-targeted anti-mitotic agent, binds to RXRα (Kd=39 nM) and selectively inhibits the p-RXRα/PLK1 interaction to induce mitotic arrest and catastrophe in cancer cells.

CD666 is a potent, selective RARgamma (RARγ) agonist.

E6060 is a potent, selective retinoic acid receptor subtype α (RAR-α) agonist with Ki of 0.2 nM, IC50 of 0.2 nM for RAR-α-mediated reporter transactivation assays.

IRX4647 is a selective RARγ agonist, regulates T cell biology and reduces syngeneic tumor growth of immune checkpoint-resistant lung cancer cell line (344SQ) when combined with anti-PD-L1.

LG101506 (LG1506) is a potent, selective and orally active RXR modulator with Ki of 2.6 nM.

XS-060 is a small molecule RXRα-targeted anti-mitotic agent, binds to RXRα (Kd=1.3 uM) and selectively inhibits the p-RXRα/PLK1 interaction to induce mitotic arrest and catastrophe in cancer cells.

STL1267 is a specific, high affinity synthetic agonist of nuclear receptor REV-ERB with EC50 of 0.13 uM and Ki of 0.16 uM, binds directly to the ligand binding domain (LBD) of REV-ERB.

BMS-336 is a potent, selective, orally active RORγt (RORC2) inverse agonist with EC50 of 39 nM in RORγt reporter assays.

ODH-08 is a novel specific small molecule ligand and agonist of RORα with KD value of 8.4 um, shows potent antifibrotic effect.

PCCR-1 is a potent, specific RORγ inhibitor with binding IC50 of 34.45 nM and 778.1 nM for human and mouse RORγ, respectively, > 300-fold selectivity over other isoforms of ROR.

W6134 (RORγ covalent inhibitor 29) is a first-in-class, potent and selective RORγ covalent inhibitor with IC50 of 0.21 uM, targets the Cys320 of RORγ.

CS27109 is a potent, selective thyroid hormone receptor-β (THR-β) agonist with AC50 value of 1.98 uM, 12.6-fold selectivity over THR-α.

AF-2112 is a small molecule inhibitor of TEAD, reduces the expression of CTGF, Cyr61, Axl and NF2, inhibits migration of human MDA-MB-231 breast cancer cells.

LM98 (TEAD inhibitor LM98) is a flufenamic acid analogue, shows strong affinity to TEAD, inhibits its autopalmitoylation and reduces the YAP-TEAD transcriptional activity.

mCMY020 is a potent, specific and covalent inhibitor of TEAD transcriptional activity with IC50 of 91.9-468.6 nM for TEAD1-4.

MYF-03-69 is a selective, covalent, irreversible TEAD inhibitor, binds with TEAD palmitate pocket, disrupts YAP-TEAD association, suppresses TEAD transcriptional activity (IC50=45 nM) and inhibits cell growth of defective Hippo signaling.

NSC682769 is a specific YAP-TEAD signaling inhibitor, blocks the association of the YAP and TEAD interaction interface, directly binds to YAP with Kd of 738 nM.

PDHPS1 is an endogenous stable peptide which is derived from the C-terminal (2090-2110) of NUMA1, inhibits the proliferation of ovarian cancer cells in vitro, regulates ovarian cancer development through targeting YAP1 signaling, binds to and interacts wi

SWTX-143 is a potent, irreversible and covalent YAP/TAZ-TEAD inhibitor with IC50 of 12 nM in luciferase reporter assays, binds to the palmitoylation pocket of all four TEAD isoforms, inhibits Hippo pathway-mutant cancer cells.

TAT-PDHPS1 is an endogenous stable peptide that inhibits the proliferation of ovarian cancer cells in vitro, regulates ovarian cancer development through targeting YAP1 signaling, binds to and interacts with protein phosphatase 2 phosphatase activator (PT

TEAD activator Q2 (Quinolinol Q2) is a small molecule activator of TEAD with EC50 of 2.6 uM in TEAD dual-luciferase reporter (DLR) assays, inhibits TEAD-palmitate interaction with IC50 of 1.7 uM.

TED-642 (TED642) is a potent, covalent, pan-TEAD-YAP1 antagonist, inhibits TEAD1/2/4 binding to YAP with IC50 of 0.9-1.2 uM.

VT-107, as an analogous to VT104, is an orally active and potent pan-TEAD auto-palmitoylation inhibitor. VT-107 can be used for the research of cancer.

Deutenzalutamide (HC-1119, MDV3100) is an androgen receptor (AR) antagonist with an IC50 of 36 nM in LNCaP prostate cells. It can be used in a treatment of advanced prostate cancer.

2,4-Thiazolidinedione (Thiazolidinedione), an insulin sensitizer, is a specific agonist of peroxisome proliferator-activated receptor (PPAR)γ. Thiazolidinedione treatment corrects impaired muscle insulin action in vivo.

Biotin-(L-Thyroxine) is the biotinylated L-Thyroxine. L-Thyroxine is a synthetic hormone for the research of hypothyroidism. DIO enzymes convert biologically active thyroid hormone (Triiodothyronine,T3) from Biotin-(L-Thyroxine) (T4).